发光二极管红光预防皮肤瘢痕的剂量范围、平行组、分脸、单盲II期研究:随机对照试验研究方案
本研究为剂量范围、随机、平行组、分脸、单盲、模拟对照的II期研究,计划纳入30例择期微面部提升术受试者,随机分三组接受发光二极管红光(LED-RL)或温度匹配模拟照射,剂量为160 J/cm2、320 J/cm2或480 J/cm2,主要终点为瘢痕柔韧性的差异。
要点
- LED-RL在I期试验中于160 J/cm2至480 J/cm2剂量下在正常人体皮肤上显示安全且可耐受。
- 本研究评估LED-RL限制术后皮肤纤维化的疗效,主要终点为瘢痕柔韧性差异。
- 术后早期给予LED-RL光疗可能优化伤口愈合并预防过度瘢痕形成。
核心结论
- LED-RL可能通过减少真皮成纤维细胞活性和胶原产生来限制皮肤纤维化,术后早期光疗可能优化伤口愈合并预防过度瘢痕形成。
研究设计与样本
- CURES研究为剂量范围、随机、平行组、分脸、单盲、模拟对照的II期研究,计划纳入30例接受择期微面部提升手术的受试者。
- 受试者随机分配至三组,接受LED-RL光疗或温度匹配模拟照射至耳周切口部位,剂量分别为160 J/cm2、320 J/cm2或480 J/cm2。
- 治疗自术后1周(术后第4-8天)开始,每周3次,连续3周,随后在30天、3个月和6个月进行疗效评估。
主要发现
- 两项I期临床试验(STARS 1和STARS 2)证明LED-RL在160 J/cm2至480 J/cm2剂量下在正常人体皮肤上安全且可耐受。
- 体外数据显示LED-RL可调节参与皮肤纤维化的关键细胞和分子过程。
关键数值与推荐
- 主要终点为LED-RL治疗部位与对照部位之间瘢痕柔韧性的差异,通过皮肤弹性和硬度测量确定。
- 次要结局包括瘢痕的临床和摄影评估、3D皮肤成像分析、组织学和分子分析以及不良事件。
临床怎么用
- 作者认为LED-RL光疗在术后早期给药可能优化伤口愈合并预防过度瘢痕形成。
- 作者认为本研究结果可能改变纤维化皮肤病的当前治疗模式,并帮助开创LED-RL作为一种安全、非侵入性、成本效益高、便携的居家瘢痕疗法。
局限性
- 原文未报告局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Skin fibrosis is a significant global health problem that affects over 100 million people annually and has a profoundly negative impact on quality of life. Characterized by excessive fibroblast proliferation and collagen deposition, skin fibrosis underlies a wide spectrum of dermatologic conditions ranging from pathologic scars secondary to injury (e.g., burns, surgery, trauma) to immune-mediated diseases. Effective anti-scarring therapeutics remain an unmet need, underscoring the importance of developing novel approaches to treat and prevent skin fibrosis. Our in vitro data show that light emitting diode-red light (LED-RL) can modulate key cellular and molecular processes involved in skin fibrosis. In two phase I clinical trials (STARS 1 and STARS 2), we demonstrated the safety and tolerability of LED-RL at fluences of 160 J/cm2 up to 480 J/cm2 on normal human skin. METHODS/DESIGN: CURES (Cutaneous Understanding of Red-light Efficacy on Scarring) is a dose-ranging, randomized, parallel group, split-face, single-blind, mock-controlled phase II study to evaluate the efficacy of LED-RL to limit post-surgical skin fibrosis in subjects undergoing elective mini-facelift surgery. Thirty subjects will be randomly allocated to three treatment groups to receive LED-RL phototherapy or temperature-matched mock irradiation (control) to either periauricular incision site at fluences of 160 J/cm2, 320 J/cm2, or 480 J/cm2. Starting one week post-surgery (postoperative days 4-8), treatments will be administered three times weekly for three consecutive weeks, followed by efficacy assessments at 30 days, 3 months, and 6 months. The primary endpoint is the difference in scar pliability between LED-RL-treated and control sites as determined by skin elasticity and induration measurements. Secondary outcomes include clinical and photographic evaluations of scars, 3D skin imaging analysis, histological and molecular analyses, and adverse events. DISCUSSION: LED-RL is a therapeutic modality of increasing importance in dermatology, and has the potential to limit skin fibrosis clinically by decreasing dermal fibroblast activity and collagen production. The administration of LED-RL phototherapy in the early postoperative period may optimize wound healing and prevent excessive scarring. The results from this study may change the current treatment paradigm for fibrotic skin diseases and help to pioneer LED-RL as a safe, non-invasive, cost-effective, portable, at-home therapy for scars. TRIAL REGISTRATION: ClinicalTrials.gov, NCT03795116 . Registered on 20 December 2018.
引用
- Nguyen JK, Weedon J, Jakus J, et al. A dose-ranging, parallel group, split-face, single-blind phase II study of light emitting diode-red light (LED-RL) for skin scarring prevention: study protocol for a randomized controlled trial. Trials. 2019. PMID: 31307501. doi:10.1186/s13063-019-3546-6
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。